2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Emerging Technologies, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, B Cell Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2272 Tumor burden at ciltacabtagene autoleucel (cilta-cel) infusion as a predictor for clinical outcomes in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in CARTITUDE-4

Maximilian Merz, MD, Binod Dhakal, MD, MS2, Hermann Einsele, MD, PhD3, Niels van de Donk, MD, PhD4, Salomon Manier, MD, PhD5, Xavier Leleu Sr, MD, PhD6, Simon Harrison, MBBS, FRCPath, MRCP, PhD, FRACP7, Maria-Victoria Mateos Jr, MD, PhD8, Surbhi Sidana, MD9, Nina Benachour10, Arnab Ghosh, MD, PhD11, Carolina Lonardi, PharmD12, Quanlin Li13, Agnes Balogh14, Chalmer Tomlinson15, Neha Bhise16, Katherine Li, MS17, Vicki Plaks, PhD18, Tamar Lengil, PhD19, Nikoletta Lendvai, MD, PhD20, Chris Del Corral21, Nitin Patel22, Vrinda Mahajan23, Paula Rodriguez Otero, MD, PhD24, Carlos Fernandez de Larrea, MD, PhD25, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD26, Joaquin Martinez-Lopez Sr, MD, PhD27
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States, University Hospital of Leipzig, Leipzig, Germany
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Universitätsklinikum Würzburg, Würzburg, Germany
4 Amsterdam University Medical Center, Amsterdam, Netherlands
5 University of Lille, Lille, France
6 Hôpital La Milétrie, Poitiers, France, Poitiers University Hospital, Poitiers, France
7 Melbourne and Royal Melbourne Hospital, Melbourne, Victoria, Australia, University of Melbourne, Parkville, Victoria, Australia
8 University Hospital of Salamanca, Salamanca, Spain
9 Stanford University School of Medicine, Stanford, California, United States
10 Johnson & Johnson, Beerse, Belgium
11 Johnson & Johnson, Raritan, New Jersey, United States
12 Johnson & Johnson, Buenos Aires, Argentina
13 Johnson & Johnson, Apex, North Carolina, United States
14 Johnson & Johnson, Beerse, Belgium
15 Johnson & Johnson, Raritan, New Jersey, United States
16 Johnson & Johnson, Raritan, New Jersey, United States
17 Johnson & Johnson, Spring House, Pennsylvania, United States
18 Johnson & Johnson, Spring House, Pennsylvania, United States
19 Johnson & Johnson, Raritan, New Jersey, United States
20 Johnson & Johnson, Raritan, New Jersey, United States
21 Legend Biotech USA Inc, Somerset, New Jersey, United States
22 Legend Biotech USA Inc, Somerset, New Jersey, United States
23 Legend Biotech USA Inc, Somerset, New Jersey, United States
24 CIMA, Pamplona, Navarra, Spain
25 Hospital Clínic de Barcelona, Barcelona, Spain, University of Barcelona, Barcelona, Spain
26 NHS Foundation Trust, London, United Kingdom
27 Complutense University CNIO, Madrid, Spain

Introduction: In the phase 3 CARTITUDE-4 study (NCT04181827), a single cilta-cel infusion reduced the risk of disease progression or death by 71% and the risk of death by 45% vs standard-of-care in pts with lenalidomide-refractory RRMM after 1-3 prior lines of therapy (Einsele Lancet Oncol 2026). Pts who achieved partial response (PR) or better to bridging therapy (BT) had longer progression-free survival (PFS), overall survival (OS), and improved safety outcomes, vs those who did not (Dhakal ASH 2025; Mina ASCO 2026). Absolute tumor burden at infusion may provide prognostic insights as well. Here, we report CARTITUDE-4 subgroup analyses evaluating the association between tumor burden at cilta-cel infusion, measured by serum soluble B-cell maturation antigen (sBCMA), and clinical outcomes, including progression-free survival (PFS), OS, and safety, assessed both independently and in combination with response to BT.

Methods: In CARTITUDE-4, pts in the cilta-cel arm underwent apheresis, received ≥1 cycle of BT (physician’s choice) with either pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone, underwent lymphodepletion (cyclophosphamide and fludarabine), and then received a single cilta-cel infusion 5-7 days after the start of lymphodepletion. As part of an exploratory analysis, tumor burden at cilta-cel infusion was assessed by serum sBCMA level (a surrogate for tumor burden), classified as low (≤5.81µg/L) or high (>5.81µg/L). A post-hoc logistic regression model identified this cutoff as the threshold most associated with 2-year disease-free status, and it was confirmed by sensitivity analyses using two alternative methods (Youden's J index and Matthews Correlation Coefficient). Response to BT (before lymphodepletion) was assessed per International Myeloma Working Group (IMWG) response criteria. PFS, assessed using a validated computerized algorithm, and OS were analyzed in the cilta-cel as-treated population (randomized pts who received cilta-cel infusion as study treatment) and were measured from the time of cilta-cel infusion.

Results: Of the 208 pts randomized to cilta-cel, 176 received cilta-cel as study treatment. Median follow-up was 30.5 months (mo). Pts with a low tumor burden (n=69) had higher 30-mo PFS (83.7%; 95%CI, 71.5-91.0) vs those with high tumor burden (n=107) (58.4%; 95%CI, 48.4-67.2) with an HR of 0.30 (95%CI, 0.16-0.58). The 30-mo OS rate was also higher in pts with low tumor burden (91.7%; 95%CI, 80.8-96.5) vs those with high tumor burden (79.4%; 95%CI, 70.4-85.9) with an HR of 0.32 (95%CI, 0.12-0.83). Of the 176 pts who received cilta-cel as study treatment, all received BT before cilta-cel infusion and 173 were evaluable for BT response. Of the 112 pts who responded to BT (≥PR), half (n=56) achieved low tumor burden. These pts had improved 30-mo outcomes vs those with a high tumor burden (n=56), including higher PFS (86.5 vs 61.6%) and OS rates (92.7 vs 85.6%). Pts with low tumor burden had a lower rate of cytokine release syndrome vs those with high tumor burden (52.2 vs 91.6%). Rates of non-relapse mortality (5.8 vs 15.0%) and prolonged grade 3/4 neutropenia (4.3 vs 14.0%) were lower in pts with low tumor burden vs those with high tumor burden. In the low tumor burden group, no movement and neurocognitive treatment-emergent adverse events or fatal infections were reported. A strong correlation was observed between sBCMA level at cilta-cel infusion and free light chain (FLC) difference (Pearson correlation coefficient: 0.68 [95%CI, 0.59-0.75]).

Conclusions: Building on the importance of achieving an optimal response to BT before cilta-cel infusion, this CARTITUDE-4 analysis shows that lower tumor burden at cilta-cel infusion, as measured by sBCMA, was associated with improved long-term disease control, OS, and reduced toxicity. Pts who achieved ≥PR to BT and also achieved low tumor burden before infusion had the highest 30-mo PFS (86.5%) and OS rates (92.7%). This finding is consistent with prior reports linking a higher effector-to-target ratio, defined by peak CAR-T expansion relative to tumor burden, with improved PFS and OS. The findings suggest that absolute residual disease burden at cilta-cel infusion as measured by sBCMA, which correlates with FLC difference, may provide clinically meaningful prognostic information for efficacy and safety outcomes, in addition to conventional IMWG response-based assessment of relative tumor reduction.

Maximilian Merz, MD: Sanofi - Honoraria; BMS - Honoraria; Johnson & Johnson - Honoraria; Takeda - Honoraria; Pfizer - Honoraria; AbbVie - Honoraria; Stemline Therapeutics - Honoraria; Amgen - Honoraria; Roche/Genentech - Research Funding; BMS - Research Funding; SpringWorks Therapeutics - Research Funding; Sanofi - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony)